GenScript ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies ...Middle East

SEOUL, South Korea, July 12, 2022 /PRNewswire/ -- On the July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer,...

Hence then, the article about genscript probio signs mou to form strategic partnership with act therapeutics to development of new car t cell therapies was published today ( Wednesday 13/07/2022 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( GenScript ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies )

Also on site :

• Rooster Runs Wild: Director Zach Braff Breaks Down Greg's Night Out In Episode 4 — And Working With John C. McGinley Across Two Shows
• Israeli police bar priest from Jerusalem’s Holy Sepulchre on Palm Sunday
• Iranian academic describes US-Israeli attacks on Iran’s universities